Serafin Morales
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Year:
2026
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Purpose: Endocrine-based therapy is the initial primary treatment option for hormone receptor–positive and human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (mBC). However, patients eventually experience disease progression due to resistance to endocrine therapy. Molibresib (GSK525762) is a small-molecule inhibitor of bromodomain and extraterminal (BET) family proteins (BRD2, BRD3, BRD4, and BRDT). Preclinical data suggested that the combination of molibresib with endocrine therapy might overcome endocrine resistance. This study aimed to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy [objective response rate (ORR)] of molibresib combined with fulvestrant in women with HR+/HER2− mBC. Patients and Methods: In this phase I/II dose-escalation and dose-expansion study, patients received oral molibresib 60 or 80 mg once daily in combination with intramuscular fulvestrant. Patients enrolled had relapsed/refractory, advanced/metastatic HR+/HER2− breast cancer with disease progression on prior treatment with an aromatase inhibitor, with or without a cyclin-dependent kinase 4/6 inhibitor. Results: The study included 123 patients. The most common treatment-related adverse events (AE) were nausea (52%), dysgeusia (49%), and fatigue (45%). At a 60-mg dosage of molibresib, >90% of patients experienced treatment-related AE. Grade 3 or 4 treatment-related AE were observed in 47% and 48% of patients treated with molibresib 60 mg and molibresib 80 mg, respectively. The ORR was 13% [95% confidence interval (CI), 8–20], not meeting the 25% threshold for proceeding to phase II. Among 82 patients with detected circulating tumor DNA and clinical outcome at study enrollment, a strong association was observed between the detection of copy-number amplification and poor progression-free survival (HR, 2.89; 95% CI, 1.73–4.83; P < 0.0001). Conclusions: Molibresib in combination with fulvestrant did not demonstrate clinically meaningful activity in this study.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (15)
Jeremy Braybrooke
Honorary Associate Professor
University of Bristol
Ana Velasco
BIOLOGIST
Hospital Universitari Arnau de Vilanova
Sara Lopez-Tarruella
ASSOCIATE PROFESSOR
Universidad Complutense de Madrid
Isabel Blancas
Profesora Asociada Contratada Laboral
Universidad de Granada
Joseph A. Sparano
Chief, Division of Hematology/Oncology; Deputy Director, Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Eva Parisi
Institut de Recerca Biomèdica de Lleida
Alfonso Cortés
-
Maria Alba Sorolla
Institut de Recerca Biomèdica de Lleida Fundació Doctor Pifarré
Juan Rafael de la Haba Rodríguez
ESPECIALISTA ONCOLOGIA MÉDICA
Universidad de Córdoba
In Hae Park
Professor
Korea University
María José Bueno
Staff Scientist
Centro Nacional de Investigaciones Oncológicas
Guillermo Villacampa Javierre
Biostatistician
Vall d´Hebron Institute of Oncology
Cristina Saura Manich
Associate Professor
Universitat Autònoma de Barcelona (UAB)
Eva M. Ciruelos-Gil
Universidad Complutense de Madrid
Xavier Gonzàlez Farré
Associate professor
Universitat Internacional de Catalunya
Make your next move.
Prepare your application
Review drafts before you send them.